Overall, there was no statistically significant difference in OS between patients exhibiting lower or higher intensity of EIF4G2 protein staining, although there was a slight trend towards lower survival in the low expressers (Supplementary Fig.
← all excerpts
Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients.
1
—
—